MichaelDGordonMD

PubMed

• Measurements of the Electroweak Diboson Production Cross Sections in Proton-Proton Collisions at s =5.02 TeV Using Leptonic Decays
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Physical Review Letters. 2021 Nov 5
• Combined searches for the production of supersymmetric top quark partners in proton-proton collisions at root s=13 TeV
  Armen Tumasyan, Wolfgang Adam, Janik Walter Andrejkovic, Thomas Bergauer, Suman Chatterjee, Marko Dragicevic, Alberto Escalante Del Valle, Rudolf Fruehwirth, Manfred J...> ;The European Physical Journal. C, Particles and Fields. 2021 Nov 3
• 1 citations
  Observation of a New Excited Beauty Strange Baryon Decaying to Ξb- π+π-
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Physical Review Letters. 2021 Jun 25
• 6 citations
  Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.
  Hamim Zahir, Fumiaki Kobayashi, Cynthia Zamora, Roohi Gajee, Michael S. Gordon, Hani M. Babiker, Qiang Wang, Jonathan Greenberg, Andrew J. Wagner> ;Journal of Clinical Pharmacology. 2021 Mar 1
• 36 citations
  Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
  Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean-Pierre Delord, Michael S. Gordon, Joseph K...> ;Clinical Cancer Research. 2021 Feb 10
• 25 citations
  Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
  Suzanne George, Robin L. Jones, Sebastian Bauer, Yoon-Koo Kang, Patrick Schöffski, Ferry A.L.M. Eskens, Olivier Mir, Phillipe A. Cassier, César Serrano, William D. Tap...> ;The Oncologist. 2021 Apr 1
• 29 citations
  Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors.
  Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael S. Gordon, Philip Mallinder...> ;Clinical Cancer Research. 2020 Dec 1
• 17 citations
  Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
  Johanna C. Bendell, Sunil Sharma, Manish R. Patel, Kevin S Windsor, Zev A. Wainberg, Michael S. Gordon, Jordan Berlin, Carrie Baker Brachmann, Marianna Zavodovskaya, J...> ;The Oncologist. 2020 Nov 1
• 50 citations
  Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety ana...
  Andrea B. Apolo, John Allan Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Theodore Gourdin, Luc Dirix, Keun Wook Lee, Matthew H. Tay...> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
• 49 citations
  Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
  Martin H. Voss, Michael S. Gordon, Monica M. Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David Smith, Andrés Cervantes, Igor Puzanov, Roberto Pili, Ding Wang,...> ;British Journal of Cancer. 2020 Sep 11
• 17 citations
  Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.
  Gino K. In, Kelsey Poorman, Michelle Saul, Steven J. O'Day, Jeffrey M. Farma, Anthony J. Olszanski, Michael S. Gordon, Jacob Stephen Thomas, Burton L. Eisenberg, Lawre...> ;Oncotarget. 2020 Aug 18
• 50 citations
  Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
  Filip Janku, Albiruni Ryan Abdul Razak, Ping Chi, Michael Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, Jonathan C. Trent, Hans Gelderblom, Neeta S...> ;Journal of Clinical Oncology. 2020 Aug 17
• 10 citations
  Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma
  Bradley Alexander McGregor, Michael S. Gordon, Ronan Flippot, Neeraj Agarwal, Saby George, David I. Quinn, Mark Rogalski, Thomas Hawthorne, Tibor Keler, Toni K. Choueiri> ;Investigational New Drugs. 2020 May 29
• 12 citations
  Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer
  Anne C. Chiang, Lecia V. Sequist, Jill Gilbert, Paul Conkling, D. S. Thompson, J. Paul Marcoux, Scott N. Gettinger, Marcin Kowanetz, Luciana Molinero, Carol O'Hear, Ma...> ;Clinical Lung Cancer. 2020 May 12
• 26 citations
  Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer.
  Matthew D. Hellmann, Scott N. Gettinger, Laura Q.M. Chow, Michael S. Gordon, Mark M. Awad, Edward Cha, Xiaohua Gong, Gongfu Zhou, Christopher James Walker, Lance Leopo...> ;International Journal of Cancer. 2020 Mar 6
• 44 citations
  A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
  Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael Millward, Wei Zhang, Ling Gao, Amanda K. Sykes, Melinda D. W...> ;Molecular Cancer Therapeutics. 2020 Feb 1
• 23 citations
  Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
  David E. Gerber, Jeffrey R. Infante, Michael S. Gordon, Sarah B. Goldberg, Miguel Martin, Enriqueta Felip, Maria Martinez Garcia, Joan H. Schiller, David R. Spigel, Ju...> ;Clinical Cancer Research. 2020 Jan 15
• 10 citations
  Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escal...
  Peter H. O'Donnell, Hendrick Tobias Arkenau, Srikala S. Sridhar, Michael Ong, Alexandra Drakaki, Alexander I. Spira, Jingsong Zhang, Michael S. Gordon, Arnold Degboe, ...> ;Cancer. 2020 Jan 15
• 21 citations
  A Phase 1 Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults With Advanced Cancers or Lymphoma.
  Monica M. Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold N. Keer, Aram Oganesian, Xiang Yao Su, Simon...> ;Clinical Cancer Research. 2020 Jan 3
• 52 citations
  Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical ...
  Gayle S. Jameson, Erkut Borazanci, Hani M. Babiker, Elizabeth Poplin, Anna A. Niewiarowska, Michael S. Gordon, Michael T. Barrett, Adam Rosenthal, Amy Stoll-D'Astice, ...> ;JAMA Oncology. 2020 Jan 1
• Individual differences in the acoustic properties of human skulls.
  Michael Gordon, Michael D. Hall, Jeremy Gaston, Ashley Foots, Jitwipar Suwangbutra> ;The Journal of the Acoustical Society of America. 2019 Sep 5
• 88 citations
  Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
  Joyce F. Liu, Michael S. Gordon, Jennifer Taylor Veneris, Fadi Braiteh, Ani Sarkis Balmanoukian, Joseph Paul Eder, Ana Oaknin, Erika Hamilton, Yulei Wang, Indrani Sark...> ;Gynecologic Oncology. 2019 Aug 1
• 159 citations
  Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
  , , , , , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2019 Jun 1
• 11 citations
  First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed...
  Christophe Massard, Jean-Charles Soria, Jürgen Krauss, Michael S. Gordon, Albert C. Lockhart, Erik Rasmussen, Vijay V. Upreti, Sonal K. Patel, Gataree Ngarmchamnanrith...> ;Cancer Chemotherapy and Pharmacology. 2019 Mar 26
• 18 citations
  Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
  Beth A. Hellerstedt, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Dana T. Aftab, David A. Ramies, Michael S. Gordon, Primo N. Lara> ;Clinical Lung Cancer. 2019 Mar 1
• Join now to see all